HEPARIN 30,000 IU Heumann cream 40 g, superficial phlebitis, blunt injuries

Heparin Heumann Creme, HEPARIN 30,000 IU Heumann cream, superficial phlebitis, blunt injuries

Active ingredient: Heparin sodium

For the supportive treatment of acute swelling conditions after blunt injuries (bruises bruises) (30,000 IU 60,000 IU) and superficial phlebitis, if this cannot be treated by compression (60,000 IU).

For information on risks and side effects, read the package insert and ask your doctor or pharmacist.

 

Active Heparin Heumann Creme, HEPARIN 30,000 IU Heumann cream, superficial phlebitis, blunt injuries ingredients

 

• 300 IU of pork heparin sodium

• Auxiliary Heparin Heumann Creme, HEPARIN 30,000 IU Heumann cream, superficial phlebitis, blunt injuries materials

  • Purified water
  • Isopropanol
  • Decyl oleate
  • Macrogol 400
  • Isopropyl myristate
  • Paraffin, thick
  • Carbomer
  • Ammonium hydroxide for pH adjustment
  • Disodium edetat-2-water
  • Perfume oil

  • HEPARIN Indication application

    • The medicinal product contains heparin sodium, an active ingredient from the group of mucopolysaccharides.
    • This group is characterized by anticoagulant activities and reduces swelling.
    • The drug is used for the supportive treatment of acute swelling conditions after blunt injuries (bruises bruises).

    •  

      HEPARIN dosage

      • Always use the medicine exactly as directed. Please ask your doctor or pharmacist if you are not sure.
        • Unless otherwise prescribed by your doctor, the usual dose is
          • The drug should be applied thinly and evenly to the affected area 2 to 3 times a day.

          • • •  

                • Duration of application
                  • The doctor decides on the duration of the application. Unless otherwise prescribed, the drug must not be used for more than 10 days.

                  • •  

                      • Please talk to your doctor or pharmacist if you have the impression that the effect of the medicine is too strong or too weak.

                      •  

                        • If you have any further questions on the use of the medicinal product, ask your doctor or pharmacist.

                        • HEPARIN way

                          • To apply on skin.

                          • Side effects

                            • Like all medicines, the medicine can have side effects, but not every person treated will experience them.
                              • The frequency of side effects is based on the following categories:
                                • Very often more than 1 in 10 people
                                • Commonly affects 1 to 10 out of 100 people
                                • Occasionally 1 to 10 out of 1,000 people
                                • Rarely affects 1 to 10 users in 10,000
                                • Very rarely less than 1 in 10,000 people treated
                                • Not known frequency cannot be estimated from the available data
                                • • possible side effects
                                    • skin
                                      • Very rare: allergic reactions when used on the skin, such as reddening of the skin and itching, which usually disappear quickly after discontinuation of the preparation.
                                      • The drug should be discontinued if allergic skin reactions occur. Please inform your doctor about this. No further measures are necessary.
                                      • • Blood and hematopoietic system
                                          • Not known: The frequency of occurrence of heparin-induced, antibody-mediated thrombocytopenia type II (reduction in the number of blood platelets <100,000 µl or a rapid decrease in the number of platelets to <50% of the initial value), with arterial and venous thromboses or embolisms that are fatal has not yet been investigated when applied locally to the skin. However, since the absorption of heparin after topical application through healthy skin has been described, this risk cannot be excluded with certainty. Increased vigilance is therefore indicated.
                                          • In patients with no impending hypersensitivity to heparin, the platelet count usually begins to decrease 6-14 days after the start of treatment. In patients with hypersensitivity to heparin, this decrease may occur within hours.
                                          • • • Please inform your doctor or pharmacist if any of the side effects gets serious, or if you notice side effects not listed here.

                                              • • HEPARIN 30,000 IU Heumann cream, superficial phlebitis, blunt injuries Interactions

                                                  • When using the drug with other drugs
                                                    • Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.
                                                    • There are no known interactions with other medicinal products with topical application.

                                                    • •  

                                                        Contraindications

                                                        • The drug must not be used
                                                          • if you are allergic (hypersensitive) to sodium heparin or any of the other ingredients of the cream,
                                                          • if you have an acute or known history of allergic drop in the number of blood platelets (thrombocytopenia type II) due to heparin.

                                                          • •  

                                                              pregnancy and breast feeding period

                                                              • pregnancy and breast feeding period
                                                                • Previous experience with the use in pregnant and breastfeeding women has not produced any indications of harmful effects. Heparin does not cross the placenta and does not pass into breast milk.
                                                                • The medicine must not be used in the breast area during breastfeeding.
                                                                • Ask your doctor or pharmacist for advice before taking using any medicine.

                                                                • •  

                                                                    HEPARIN 30,000 IU Heumann cream, superficial phlebitis, blunt injuries Patient information

                                                                    • Special care is required when using the drug
                                                                      • The drug should not be applied to open wounds and or weeping eczema.
                                                                      • If new symptoms appear that could indicate a thrombosis or pulmonary embolism, such as
                                                                        • Swelling and sensation of warmth in the affected part of the body,
                                                                        • reddened and tight skin, possibly blue,
                                                                        • Sense of tension and pain in the foot, calf and hollow of the knee (relief when lying up)
                                                                        • Sudden shortness of breath, chest pain, and weakness collapse
                                                                        • the presence of heparin-induced thrombocytopenia type II must be excluded and the platelet count (thrombocyte count) checked immediately.
                                                                        • • Regular checks of platelet counts are required each time heparin is used.
                                                                          • Checks of the platelet count should be carried out:
                                                                            • before starting heparin administration
                                                                            • on the 1st day after the start of the heparin administration
                                                                            • then every 3 – 4 days until the end of the heparin treatment.
                                                                            • • If medicinal products that interfere with blood clotting are used at the same time, an increased risk of bleeding cannot be ruled out. Bruising may be more common or widening.
                                                                              • During treatment with the medicine, injections into the muscle should be avoided because of the risk of bruising (hematomas).
                                                                              • • Title	Default Title